Financhill
Back

89bio Quote, Financials, Valuation and Earnings

89bio Price Quote

$7.93

89bio Key Stats

Sell
18
89bio (ETNB) is a Sell

Day range:
$6.60 - $7.95
52-week range:
$6.43 - $16.63
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.00
P/B ratio:
2.47%

Volume:
4.5M
Avg. volume:
1.3M
1-year change:
-22.48%
Market cap:
$932.4M
Revenue:
$0
EPS:
$-2.91

How Much Does 89bio Make?

Data Unavailable

Is 89bio Growing As A Company?

Data Unavailable

89bio Stock Price Performance

  • Did 89bio Stock Go Up Last Month?
    89bio share price went down by -0.63% last month
  • Did ETNB's Share Price Rise Over The Last Year?
    ETNB share price fell by -22.48% over the past 1 year

What Is 89bio 52-Week High & Low?

  • What Is 89bio’s 52-Week High Share Price?
    89bio has traded as high as $16.63 over the past 52 weeks
  • What Is 89bio’s 52-Week Low Share Price?
    89bio has traded as low as $6.43 over the past 52 weeks

89bio Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy 89bio?

Data Unavailable

Is 89bio Cash Flow Positive?

Data Unavailable

89bio Return On Invested Capital

Data Unavailable

89bio Earnings Date & Stock Price

  • What Is 89bio's Stock Price Today?
    A single share of ETNB can be purchased today for 7.93
  • What Is 89bio’s Stock Symbol?
    89bio trades on the nasdaq under the ticker symbol: ETNB
  • When Is 89bio’s Next Earnings Date?
    The next quarterly earnings date for 89bio is scheduled on February 28, 2025
  • When Is ETNB's next ex-dividend date?
    89bio's next ex-dividend date is May 12, 2020
  • How To Buy 89bio Stock?
    You can buy 89bio shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.

89bio Competitors

  • Who Are 89bio's Competitors?
    Below is a list of companies who compete with 89bio or are related in some way:
    • Akero Therapeutics Inc (AKRO)
    • Eli Lilly and Co (LLY)
    • Madrigal Pharmaceuticals Inc (MDGL)
    • NovaBay Pharmaceuticals Inc (NBY)
    • Viking Therapeutics Inc (VKTX)

89bio Dividend Yield

Data Unavailable

89bio Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -116.5%
Revenue: 0% -100%

Analyst Recommendations

Buy Recommendations: 7
Hold Recommendations: 2
Sell Recommendations: 0
Price Target: 0.00
Downside from Last Price: -100%

Major Shareholders

Data Unavailable